US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

19.02

+0.48002.59%

Volume:212.42K

Turnover:3.97M

Market Cap:549.15M

PE:-103.10

High:19.06

Open:18.51

Low:17.89

Close:18.54

Loading ...

Overview Company News Filings

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA

J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use

4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now

Leerink Partners Keeps Their Buy Rating on Castle Biosciences (CSTL)

Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study

AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer

NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts

Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate

MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

Kymera Provides Pipeline Objectives for 2025, Stock Gains

TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise

Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz

Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook

Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CSTL/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSTL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","market":"US","secType":"STK","nameCN":"Castle Biosciences, Inc.","latestPrice":19.02,"timestamp":1750274717124,"preClose":18.54,"halted":0,"volume":212422,"delay":0,"floatShares":26464372,"shares":28872315,"eps":-0.184478,"marketStatus":"Trading","change":0.48,"latestTime":"06-18 15:25:17 EDT","open":18.51,"high":19.0625,"low":17.8862,"amount":3967559.69995,"amplitude":0.063447,"askPrice":19.05,"askSize":416,"bidPrice":19,"bidSize":34,"shortable":3,"etf":0,"ttmEps":-0.184478,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1750276800000},"marketStatusCode":2,"adr":0,"listingDate":1564027200000,"exchange":"NASDAQ","adjPreClose":18.54,"preHourTrading":{"tag":"盘前","latestPrice":18.54,"preClose":18.54,"latestTime":"08:00 EDT","volume":1,"amount":18.54,"timestamp":1750248000927},"postHourTrading":{"tag":"盘后","latestPrice":18.54,"preClose":18.54,"latestTime":"19:14 EDT","volume":10873,"amount":201587.63,"timestamp":1750202069955},"volumeRatio":0.472069,"impliedVol":0.293,"impliedVolPercentile":0.016},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","floatShares":26464372,"roa":"-1.79%","roe":"-1.20%","lyrEps":0.656862,"volumeRatio":0.472069,"shares":28872315,"dividePrice":0,"high":19.0625,"amplitude":0.063447,"preClose":18.54,"low":17.8862,"week52Low":15.45,"pbRate":"1.25","psRate":"1.58","week52High":35.84,"institutionHeld":0,"latestPrice":19.02,"committee":-0.848889,"eps":-0.184478,"divideRate":0,"volume":212422,"delay":0,"ttmEps":-0.184478,"open":18.51,"prevYearClose":26.65,"prevWeekClose":18.75,"prevMonthClose":15.97,"prevQuarterClose":20.02,"fiveDayClose":18.44,"twentyDayClose":16.5,"sixtyDayClose":20.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSTL\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2505779089","title":"REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2505779089","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505779089?lang=en_us&edition=fundamental","pubTime":"2025-01-23 00:37","pubTimestamp":1737563820,"startTime":"0","endTime":"0","summary":"Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application  for its lead pipeline candidate, RP1 , in combination with Bristol Myers’ BMY Opdivo  to treat adult patients with advanced melanoma.With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected on July 22, 2025.Shares of REPL were up 16.9% on Jan. 21 following the announcement of the news.The FDA also informed REPL that the agency is not currently planning to hold an advisory committee meeting related to the BLA, as it has not identified any potential review issues at this point.In the past year, shares of Replimune have rallied 50.7% against the industry’s decline of 14.8%.Replimune submitted the BLA for the RP1/Opdivo combo in advanced melanoma in November 2024.In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 30.9%.In the past 60 days, es","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/repl-stock-rises-fdas-priority-163700715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0009355771.USD","LU1291159041.SGD","LU0306806265.USD","LU1868836757.USD","REPL","LU2242652126.USD","IE00BSNM7G36.USD","LU0321505868.SGD","LU0456855351.SGD","LU1868836914.USD","BMY","LU0114720955.EUR","LU1868837136.USD","BK4532","CSTL","LU0225284248.USD","IE0002141913.USD","BK4588","BK4581","LU1032466523.USD","LU1868837300.USD","LU2242646821.SGD","LU2125154935.USD","VYGR","LU0225771236.USD","LU1430594728.SGD","LU1670711123.USD","IE00B2B36J28.USD","BK4139","LU1261432733.SGD","LU1323610961.USD","LU2133065610.SGD","LU0306807586.USD","BK4196","LU0237698245.USD","LU2360032135.SGD","LU0882574055.USD","LU1670710661.SGD","LU1571399168.USD","LU0321505439.SGD","IE00BJT1NW94.SGD","LU0061475181.USD","LU1093756325.SGD","LU1868836591.USD","LU0868494617.USD","IE00BFTCPJ56.SGD","LU1670710588.SGD","LU2125154778.USD","BK4534","LU1989771016.USD"],"gpt_icon":0},{"id":"2505727779","title":"J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2505727779","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505727779?lang=en_us&edition=fundamental","pubTime":"2025-01-23 00:15","pubTimestamp":1737562500,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application , seeking approval for Spravato  as a monotherapy for adults living with treatment-resistant depression .Spravato is presently approved in combination with an oral antidepressant to treat adults with TRD and depressive symptoms in adults with major depressive disorder  with acute suicidal ideation or behavior.Following the latest nod, Spravato became the first and only monotherapy for treating MDD in adults who have had an inadequate response to at least two oral antidepressants and are considered to have TRD.In the past year, shares of J&J have lost 7.3% compared with the industry’s decline of 5.1%.More on the Latest Nod for JNJ's Spravato as Monotherapy. The latest FDA nod for Spravato was based on data from a double-blind, multicenter, placebo-controlled study.In the past 60 days, estimates for BioMarin’s earnings per share have increased from $3.94 to $4.02 for 2025. In the past year, sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/j-js-depression-drug-spravato-161500318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0203347892.USD","LU1718418525.SGD","LU0234570918.USD","IE00B19Z3581.USD","BK4566","BK4550","LU1221951129.SGD","IE00BVYPNW00.USD","LU0122379950.USD","LU1506573853.SGD","LU1929549753.HKD","LU2133065610.SGD","SG9999002232.USD","LU1732799900.SGD","IE00BFTCPJ56.SGD","LU0882574055.USD","IE00BVYPNV92.GBP","LU2602419157.SGD","LU1066051498.USD","LU0234572021.USD","LU1066051225.USD","LU1261432733.SGD","LU1280957306.USD","LU1430594728.SGD","VYGR","LU0289739699.SGD","LU1066051811.HKD","BK4559","CSTL","LU0912757837.SGD","IE0009355771.USD","LU1732800096.USD","JNJ","LU2468319806.SGD","BK4534","BK4532","IE0034235303.USD","BK4504","BK4139","LU2089984988.USD","LU0345770308.USD","IE00BGHQF631.EUR","LU0795875086.SGD","IE00BJT1NW94.SGD","LU1244550494.USD","LU0114720955.EUR","BMRN","LU0792757196.USD","LU1585245621.USD","LU0795875169.SGD"],"gpt_icon":1},{"id":"2505729014","title":"4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2505729014","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505729014?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:10","pubTimestamp":1737551400,"startTime":"0","endTime":"0","summary":"The primary purpose of a business is to generate profits that can be reinvested in expansion or utilized for rewarding shareholders. Net profit margin is an effective tool to measure the profits reaped by a business.A higher net margin underlines a company’s efficiency in translating sales into actual profits. Moreover, this metric gives insight into how well a company is run and the headwinds weighing on it. Castle Biosciences, Inc. CSTL, OppFi, Inc. OPFI, GigaCloud Technology Inc. GCT and Qifu Technology, Inc. QFIN boast solid net profit margins.In simple terms, net profit is the amount a company retains after deducting all costs, interest, depreciation, taxes and other expenses. In fact, net profit margin can turn out to be a potent point of reference to gauge the strength of a company’s operations and its cost-control measures.Moreover, a higher net profit margin compared with its peers provides a company with a competitive edge.VGM Score of A or B: Our research shows that stocks w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/4-top-ranked-stocks-solid-131000386.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0683595622.HKD","LU0633140560.USD","BK4159","BK4122","BK4588","LU1808992512.USD","BK4503","LU2476274308.USD","LU1981816686.USD","BK4526","LU2778985437.USD","OPFI","BK4585","CSTL","BK4531","BK4196","BK4166","GCT","LU0633140727.USD","QFIN"],"gpt_icon":0},{"id":"2505175023","title":"Leerink Partners Keeps Their Buy Rating on Castle Biosciences (CSTL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505175023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505175023?lang=en_us&edition=fundamental","pubTime":"2025-01-22 11:35","pubTimestamp":1737516910,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences (CSTL – Research Report) yesterday and set a price target of $5...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-castle-biosciences-cstl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-castle-biosciences-cstl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSTL"],"gpt_icon":0},{"id":"2505204653","title":"Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2505204653","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505204653?lang=en_us&edition=fundamental","pubTime":"2025-01-21 23:43","pubTimestamp":1737474180,"startTime":"0","endTime":"0","summary":"NanobiotixNBTX shares were up around 13% during the pre-market hours on Tuesday after the company announced that it has initiated dosing in a mid-stage study evaluating a potential first-in-class radioenhancer, JNJ-1900 , to treat lung cancer patients. The candidate was added to Nanobiotix’s pipeline following a licensing deal for the global co-development and commercialization with pharma bigwig, Johnson & Johnson JNJ, in 2023.The company stated that it has dosed the first patient with JNJ-1900 in the phase II CONVERGE study to treat patients with Stage 3 unresectable non-small cell lung cancer . The eligibility criteria for this study include NSCLC patients receiving standard-of-care chemoradiation followed by consolidation immunotherapy with AstraZeneca’s Imfinzi . Per the global licensing agreement with Nanobiotix, Johnson & Johnson is responsible for funding the CONVERGE study.Nanobiotix’s pipeline comprises only JNJ-1900, which is being evaluated across multiple solid tumor indic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanobiotix-stock-gains-dosing-begins-154300753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0792757196.USD","LU0345769128.USD","BMRN","LU1023059063.AUD","IE00B42XCP33.USD","LU1032955483.USD","LU1032466523.USD","NBTX","LU0234572021.USD","LU1894683348.USD","LU0320765646.SGD","LU1929549753.HKD","SG9999002224.SGD","SSI","LU1244550494.USD","LU1674673428.USD","LU0882574055.USD","IE0034235303.USD","JNJ","LU1430594728.SGD","LU1778281490.HKD","IE00BGHQF631.EUR","IE0002270589.USD","LU2347655156.SGD","IE00BDGV0183.EUR","BK4139","LU0640476718.USD","LU0889566641.SGD","LU1196500208.SGD","LU1066051498.USD","LU1732800096.USD","LU1732799900.SGD","BK4588","LU1244550221.USD","BK4568","IE00BVYPNW00.USD","LU0122379950.USD","LU1066051811.HKD","CSTL","IE00B4R5TH58.HKD","LU1935042991.SGD","LU0795875169.SGD","IE00B3PB1722.GBP","BK4532","BK4550","LU2602419157.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU0203345920.USD"],"gpt_icon":0},{"id":"2505230363","title":"AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505230363","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505230363?lang=en_us&edition=fundamental","pubTime":"2025-01-21 03:05","pubTimestamp":1737399900,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate ,datopotamab deruxtecan , in patients with a certain type of breast cancer. The drug, developed in partnership with Japan-based Daiichi Sankyo, will be marketed under the brand name Datroway.Post the FDA’s approval, the ADC drug is approved to treat unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy.This approval came just a few weeks after Daiichi secured approval for the drug for a similar indication in Japan. The approvals in the United States and Japan are based on data from the phase III TROPION-Breast01 study, which showed that treatment with Datroway significantly reduced the risk of disease progression or death by 37% compared to the investigator’s choice of chemotherapy in the above indication.Per AstraZeneca, Datroway is part of a select group of therapies that could achieve peak annual sales of at ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-secures-fda-nod-adc-190500987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ERAS","BK4539","BK4007","AZN","LU2456880835.USD","LU0889565916.HKD","BK4231","LU2417539215.USD","LU0109394709.USD","CTMX","BK4585","BK4568","LU2236285917.USD","CSTL","BK4588","ADC","BK4139","LU1829250122.USD","BK4080","LU2462157665.USD","LU0320765992.SGD","BK4196"],"gpt_icon":0},{"id":"2505233741","title":"NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts","url":"https://stock-news.laohu8.com/highlight/detail?id=2505233741","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505233741?lang=en_us&edition=fundamental","pubTime":"2025-01-20 23:53","pubTimestamp":1737388380,"startTime":"0","endTime":"0","summary":"Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under Medicare Part D for the second round of price negotiations in 2025. Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabetes  and Wegovy injections for weight management.Any price reduction resulting from the impending negotiations will become effective in 2027.For continued coverage of its semaglutide medicines under Medicare, NVO has until Feb. 28, 2025, to decide if it will participate in negotiations or pay a large tax on U.S. sales of the drugs. Either way, investors anticipate a decline in the company's profit margins resulting in the stock price decline. The Inflation Reduction Act allows Medicare to negotiate the prices of certain prescription drugs to make them more affordable for seniors and people with disabilities.Analysis of th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-stock-down-medicare-selects-155300223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LLY","LU1868836591.USD","LU1093756168.USD","BK4534","LU1035775433.USD","LU0094547139.USD","LU0708995401.HKD","LU0320765059.SGD","BK4516","NVO","LU0058720904.USD","LU1057294990.SGD","LU0640476718.USD","IE0009355771.USD","LU2237443549.SGD","LU2264538146.SGD","LU1712237335.SGD","IE00BK4W5M84.HKD","LU0096364046.USD","SG9999001176.SGD","LU2063271972.USD","LU0114720955.EUR","LU0672654240.SGD","LU0109391861.USD","BMRN","SGXZ99366536.SGD","LU2361045086.USD","BK4566","LU0471298777.SGD","IE0002270589.USD","IE00BKVL7J92.USD","LU0006306889.USD","LU0943347566.SGD","IE00B4R5TH58.HKD","LU1804176565.USD","LU1983299246.USD","LU0820561818.USD","LU2491050154.USD","SG9999015952.SGD","LU1868837136.USD","CSTL","LU2237438978.USD","SG9999015945.SGD","LU0238689110.USD","LU0256863811.USD","LU1720051017.SGD","LU0198837287.USD","LU1551013425.SGD","LU0466842654.USD","LU1280957306.USD"],"gpt_icon":1},{"id":"2505287123","title":"Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505287123","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505287123?lang=en_us&edition=fundamental","pubTime":"2025-01-20 22:18","pubTimestamp":1737382680,"startTime":"0","endTime":"0","summary":"Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras , in combination with its anti-EGFR antibody, Vectibix , for treating KRAS G12C-mutated metastatic colorectal cancer .The regulatory body approved Lumakras plus Vectibix for treating KRAS G12C-mutated mCRC in adult patients who have previously received fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.Lumakras is presently approved for treating advanced or metastatic non-small cell lung cancer . The drug was approved in the United States in May 2021 and in the EU  in January 2022.In the past year, shares of Amgen have dropped 12.2% compared with the industry’s decline of 14.1%.Lumakras’ approval for the mCRC indication was based on data from the phase III CodeBreaK 300 study, which evaluated Lumakras plus Vectibix versus the investigator's choice of therapy in KRAS G12C–mutated mCRC.Data from the CodeBreaK 300 study also showed that treatment with Lumakras plus Vectibix demonstrated favorable ov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgens-lumakras-gets-fda-nod-141800343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU1023059063.AUD","BK4581","VYGR","SOC","LU1983299246.USD","LU0889565916.HKD","BK4533","LU0320765992.SGD","BK4213","IE00BJJMRZ35.SGD","LU1571399168.USD","IE00B4R5TH58.HKD","AMGN","LU0868494617.USD","BK4599","IE00BFTCPJ56.SGD","BK4534","LU0109394709.USD","LU2112291526.USD","LU2242652126.USD","CTMX","LU0289739699.SGD","BK4195","BK4196","LU2242646821.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4566","PFS","LU0058720904.USD","SG9999001440.SGD","LU0122379950.USD","BK4211","IE0002141913.USD","IE0009355771.USD","BK4588","BK4585","CSTL","LU1057294990.SGD","LU1061106388.HKD"],"gpt_icon":0},{"id":"2504929191","title":"Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504929191","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504929191?lang=en_us&edition=fundamental","pubTime":"2025-01-17 23:28","pubTimestamp":1737127680,"startTime":"0","endTime":"0","summary":"Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen , its investigational candidate for treating Dravet syndrome, a severe and progressive genetic epilepsy.Zorevunersen is a novel proprietary antisense oligonucleotide with the potential to become the first disease-modifying therapy to address the genetic cause of Dravet syndrome.The FDA granted a Breakthrough Therapy designation to zorevunersen for treating Dravet syndrome in December 2024.In the past year, shares of Stoke Therapeutics have rallied 94.7% against the industry’s decline of 13.6%.In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 30.6%.In the past 60 days, estimates for CytomX Therapeutics’ loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have decreased 49.5%.CTMX’s earnings beat estimates in two of the trailing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/good-idea-invest-stoke-therapeutics-152800824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["STOK","BK4139","BK4196","LENZ","VYGR","CTMX","CSTL"],"gpt_icon":0},{"id":"2504195429","title":"ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2504195429","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504195429?lang=en_us&edition=fundamental","pubTime":"2025-01-17 22:24","pubTimestamp":1737123840,"startTime":"0","endTime":"0","summary":"Tab-cel, the company’s novel T-cell immunotherapy, is already marketed in the EU under the brand name, Ebvallo, by Atara’s partner Pierre Fabre under an exclusive commercialization and license agreement.EBV+ PTLD is a rare hematologic malignancy  with a high mortality rate and occurs after patients undergo transplantation when their T-cell immune responses are compromised by immunosuppression.In the past three months, Atara shares have lost 16.8% compared with the industry’s 12.2% decline.More on the FDA’s CRL Issuance Against ATRA’s Ebvallo. Atara is eligible to receive a $60 million milestone payment from Pierre Fabre upon FDA approval of the Ebvallo BLA, providing a critical cash infusion for the company. Additionally, it will be eligible for substantial double-digit tiered royalties based on net sales and further milestones tied to Ebvallo's commercial performance. However, the FDA's CRL has also delayed the milestone payment, impacting funds the company planned to allocate for sup","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atra-stock-down-fda-issues-142400167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4585","BMRN","BK4566","CRL","LU0390134368.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4588","IE0002270589.USD","CTMX","ATRA","CSTL","BK4530","BK4196","BK4121"],"gpt_icon":0},{"id":"2504949490","title":"MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2504949490","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504949490?lang=en_us&edition=fundamental","pubTime":"2025-01-17 01:09","pubTimestamp":1737047340,"startTime":"0","endTime":"0","summary":"Shares of Mirum Pharmaceuticals MIRM were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024, along with an encouraging outlook and growth strategy for 2025.Mirum’s commercial portfolio comprises of lead product, Livmarli , which is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive familial intrahepatic cholestasis in the United States and Europe.MIRM acquired Travere Therapeutics’ bile acid products in August 2023, which added the latter’s Cholbam capsules and Chenodal tablets to its portfolio of commercialized drugs.In the past year, shares of Mirum have rallied 73.3% against the industry’s decline of 16%.Meanwhile, a new drug application seeking approval for Chenodiol for cerebrotendinous xanthomatosis  patients is currently under review in the United States. A decisi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirm-shares-rise-12-week-170900763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","CSTL","BK4139","VYGR","BK4196","MIRM"],"gpt_icon":0},{"id":"2504433569","title":"InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2504433569","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504433569?lang=en_us&edition=fundamental","pubTime":"2025-01-16 23:49","pubTimestamp":1737042540,"startTime":"0","endTime":"0","summary":"InflaRx N.V.IFRX shares gained 7.7% on Wednesday following the European Commission's  approval of marketing authorization, under exceptional circumstances, for Gohibic  to treat adult patients with acute respiratory distress syndrome  caused by SARS-CoV-2. The targeted patient population in the EU comprises individuals receiving systemic corticosteroids as standard-of-care therapy and undergoing invasive mechanical ventilation, with or without extracorporeal membrane oxygenation.The EC’s approval makes Gohibic the first and only approved treatment for SARS-CoV-2-induced ARDS in the EU. We remind the investors that in November 2024, the advisory committee to the European Medicines Agency had adopted a positive opinion recommending approval of the drug for the above indication, under exceptional circumstances. Gohibic is a first-in-class anti-C5a monoclonal antibody.More on the EC Nod for IFRX’s COVID-19-Induced ARDS Drug. The EU approval ofInflaRx’s Gohibic for the ADRS indication is ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inflarx-stock-rises-8-conditional-154900009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BLSP4452.SGD","LU2242652126.USD","LU1868837136.USD","LU0868494617.USD","SG9999001440.SGD","SG9999014559.SGD","LU0689626769.HKD","CSTL","IE00B7SZLL34.SGD","SG9999015358.SGD","PG","CTMX","LU2242646821.SGD","BK4568","LU0061475181.USD","LU1066051498.USD","IE000M9KFDE8.USD","LU1280957306.USD","LU0640476718.USD","IE00BLSP4239.USD","BK4139","BK4504","BNTX","LU0098860793.USD","LU0124676726.USD","LU1066053197.SGD","SG9999002232.USD","BK4548","BK4581","LU1868836591.USD","IE00BWXC8680.SGD","ARDS","LU2552382132.HKD","LU1868837300.USD","BK4018","LU1929549753.HKD","LU1430594728.SGD","SG9999014575.USD","BK4196","EC","LU0094547139.USD","LU2552382215.SGD","LU0320765646.SGD","BK4533","BMRN","BK4201","IE00BBT3K403.USD","IFRX","BK4551","SG9999002224.SGD"],"gpt_icon":0},{"id":"2503749996","title":"Kymera Provides Pipeline Objectives for 2025, Stock Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2503749996","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503749996?lang=en_us&edition=fundamental","pubTime":"2025-01-16 02:30","pubTimestamp":1736965800,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. KYMR announced its business goals for 2025, along with anticipated progress on its pipeline of immunology programs.Shares of KYMR have surged 47.2% in a year against the industry’s decline of 16%.Kymera is developing KT-621, an investigational, first-in-class, once-daily oral degrader of STAT6. The candidate has demonstrated dupilumab-like activity and very good safety data in preclinical models.Kymera expects to complete this phase I study and report data in the second quarter of 2025. It will also advance the candidate in a phase lb study in AD patients in the second quarter of 2025 and report data in the fourth quarter of the year.Kymera is also evaluating KT-295, an investigational, first-in-class, once-daily oral degrader of TYK2, a member of the Janus kinase  family required for Type I IFN, IL-12 and IL-23 signaling.The company expects to file an investigational new drug application for the candidate and initiate dosing in the phase I healthy volunteer c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-provides-pipeline-objectives-2025-183000231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE00B19Z3B42.SGD","SNY","BMRN","IE00BFXG1179.USD","IE0002270589.USD","IE00B19Z3581.USD","BK4196","CSTL","BK4139","BK4007","BK4588","KYMR","IE00B7SZLL34.SGD","BK4566"],"gpt_icon":0},{"id":"2503273621","title":"TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2503273621","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503273621?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:10","pubTimestamp":1736950200,"startTime":"0","endTime":"0","summary":"TG Therapeutics TGTX announced preliminary net product revenues for the fourth quarter and full-year 2024 for its marketed drug, Briumvi , which exceeded the company’s initial expectations.TGTX also provided its guidance for 2025 and outlined some expected milestones related to Briumvi label expansion studies and other pipeline candidates for 2025.Briumvi is approved for the treatment of certain adult patients with relapsing forms of multiple sclerosis .In the past year, shares of TG Therapeutics have rallied 96.2% against the industry’s decline of 14.8%.In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 33%.In the past 60 days, estimates for CytomX Therapeutics’ loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have plunged 49.5%.CTMX’s earnings beat estimates in two of the trailing four quarters while missing the same on the re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tgtx-announces-2024-preliminary-results-141000241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2023251221.USD","LU1732799900.SGD","LU1162221912.USD","LU2089284900.SGD","LU2357305700.SGD","BK4588","LU0795875169.SGD","LU1989772840.SGD","VYGR","LU1720051108.HKD","BK4516","BK4534","LU1363072403.SGD","LU2271345857.HKD","BK4585","LU0098860793.USD","LU0006306889.USD","LU0158827948.USD","LU0795875086.SGD","IE00BZ1G4Q59.USD","LU0267386448.USD","LU0314104364.USD","LU0158827781.USD","LU0225283273.USD","LU2347655156.SGD","LU1074936037.SGD","LU0912757837.SGD","CSTL","LU1720051017.SGD","LU0320765646.SGD","BK4139","LU1668664300.SGD","LU1732800096.USD","LU1989772923.USD","LU0971096721.USD","LU0106831901.USD","IE00BKVL7J92.USD","LU2089283258.USD","BK4504","TGTX","LU0106261372.USD","LU2111349929.HKD","BK4127","LU2028103732.USD","BK4581","CTMX","BK4196","LU1548497426.USD"],"gpt_icon":0},{"id":"2503056435","title":"Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2503056435","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503056435?lang=en_us&edition=fundamental","pubTime":"2025-01-14 23:14","pubTimestamp":1736867640,"startTime":"0","endTime":"0","summary":"Shares of Blueprint MedicinesBPMC rallied 18.2% on Monday driven by investor enthusiasm following the company’s announcement of its 2025 corporate outlook and growth strategy, highlighting plans to build on its established R&D and commercial expertise.Blueprint’s commercial portfolio only comprises its lead drug Ayvakit , an inhibitor of KIT and PDGFRA proteins,which was initially approved in the United States and the EU to treat gastrointestinal stromal tumors in 2020. Later, the drug’s label was expanded by respective regulatory authorities in both geographies to treat advanced and indolent systemic mastocytosis .The company anticipates reporting its fourth-quarter and full-year 2024 results in February 2025. In October 2024, Blueprint projected Ayvakit product revenues in the range of $475-$480 million for the year, marking growth of more than 130% compared with 2023. The growth trajectory of Ayvakit sales is expected to continue rising in 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blueprint-stock-soars-18-encouraging-151400664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BPMC","BK4505","BK4213","BK4196","BK4139","HALO","LU0053671581.USD","CSTL","CTMX","SM"],"gpt_icon":0},{"id":"2503555448","title":"Biogen Offers to Buy Remaining Stake in Sage Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2503555448","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503555448?lang=en_us&edition=fundamental","pubTime":"2025-01-14 04:00","pubTimestamp":1736798400,"startTime":"0","endTime":"0","summary":"Sage Therapeutics  said Biogen  has made an unsolicited offer to acquire the rest of SAGE shares.Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will review the offer.Sage Therapeutics SAGE announced that its partner Biogen BIIB has made an unsolicited, non-binding proposal offer to acquire the SAGE shares that it does not already own for $7.22per share. The offer price represents a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Friday.At present, Biogen owns a 10.2% stake in SAGE, per a SEC filing by the company. Sage Therapeutics’ board will review and evaluate the offer and will come to a final decision.SAGE’s stock was up 46% in after-hours trading on Friday in response to the news while Biogen was down slightly.Biogen’s shares have declined 40%, while Sage Therapeutics’ stock has been down 79.1% in the past year, compared with a decrease of 15.9% for the industry.In September, Biogen terminated its rights under the collaboration and lic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-offers-buy-remaining-stake-200000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4533","IE00B19Z9Z06.USD","ABVC","BK4581","BK4588","SAGE","BK4561","PPD","LU0109394709.USD","BK4532","BK4144","BK4121","LU0320765992.SGD","BK4530","ET","LU0234570918.USD","BK4585","BK4590","CSTL","MCI","BK4196","IE00B894F039.SGD","IE00B19Z9P08.USD","LU0889565916.HKD","BIIB","PBYI"],"gpt_icon":0},{"id":"2503353959","title":"PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2503353959","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503353959?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:43","pubTimestamp":1736786580,"startTime":"0","endTime":"0","summary":"Shares of Pacira BioSciences PCRX gained 11.1% on Friday after the company shared better-than-expected preliminary fourth-quarter 2024 sales figures for its marketed products.Additionally, the company unveiled a five-year growth strategy aimed at accelerating its transformation into an innovative biopharmaceutical company and establishing itself as a leader in musculoskeletal pain and related areas. This has also likely contributed to the stock price rally.Pacira did not recognize any other revenues, comprising sales of bupivacaine liposome injectable suspension and royalties, in the fourth quarter of 2024. In the year-ago period, the company recognized $2.6 million in other revenues.Pacira has outlined its ambitious \"5x30\" strategy, a growth-oriented plan designed to drive innovation and value creation by 2030. Central to this vision is the goal of treating more than three million patients annually while achieving a double-digit compounded annual growth rate in product revenues. The c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pcrx-stock-rises-11-upbeat-164300518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","CSTL","PCRX","HALO"],"gpt_icon":0},{"id":"2503534916","title":"ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz","url":"https://stock-news.laohu8.com/highlight/detail?id=2503534916","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503534916?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:40","pubTimestamp":1736786400,"startTime":"0","endTime":"0","summary":"Shares of Intra-Cellular Therapies ITCI rallied 14.9% on Friday after the company announced that it has entered into a settlement agreement with Sandoz SDZNY regarding the Caplyta  patent litigation.The settlement agreement resolves the patent litigation brought by Intra-Cellular on Sandoz for submitting an abbreviated new drug application to the FDA seeking marketing approval for a generic version ofCaplyta in the United States before applicable patents expire. The litigation is currently pending in the U.S. District Court in New Jersey.Caplyta is approved in the United States for the treatment of schizophrenia in adults. Later, its indication was expanded to treat bipolar depression in adults. Intra-Cellular’s Caplyta is currently the only approved treatment, both as monotherapy and as adjunctive therapy with lithium or valproate, for depressive episodes associated with bipolar depression in adults.In 2022, the FDA approved two new dosage strengths of Caplyta, 10.5 mg and 21 mg for p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/itci-stock-rises-15-settling-164000815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU0012050646.USD","LU0106261612.USD","ITCI","BK4139","CTMX","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","SDZNY","CSTL","BK4196","LU0053671581.USD"],"gpt_icon":0},{"id":"2503391055","title":"Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2503391055","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503391055?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:31","pubTimestamp":1736785860,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics FOLD announced preliminary total revenues for the fourth quarter and full-year 2024. The company’s top line currently comprises sales of the lead product, Galafold , which is approved for treating Fabry disease and Pombiliti + Opfolda.The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease, in September 2023.Along with the preliminary results, Amicus also outlined key strategic priorities and outlook for 2025.In the past year, shares of Amicus have plunged 31.6% compared with the industry’s decline of 16%.For full-year 2025, management expects total revenues to grow in the range of 17%-24% on a constant exchange rate .Revenues from Galafold are expected to grow in the range of 10%-15% at CER in 2025.Both Fabry disease and Pompe disease are rare diseases. Amicus is currently advancing ongoing studies to broaden labels in Fabry and Pompe diseases.Amicus expects to achieve positive GAAP net income in the second half of 2025. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amicus-posts-preliminary-2024-results-163100240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD","BK4139","CTMX","BK4566","BK4557","BK4588","BK4584","BK4596","TEVA","BK4585","BK4559","BK4007","CSTL","LU2065170008.USD","FOLD"],"gpt_icon":0},{"id":"2503853591","title":"Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2503853591","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503853591?lang=en_us&edition=fundamental","pubTime":"2025-01-13 23:13","pubTimestamp":1736781180,"startTime":"0","endTime":"0","summary":"Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor sasanlimab in patients with BCG-nave, high-risk, non-muscle invasive bladder cancer , including patients with carcinoma in-situ .Results from the study showed that treatment with subcutaneously administered sasanlimab combined with standard-of-care BCG vaccine resulted in a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival  compared to BCG alone.Though Pfizer did not share any numbers supporting this data, management mentioned that the study results mark a significant milestone in a therapeutic area that has seen little progress over the past 30 years. It also mentioned that the drug’s safety profile was consistent with other PD-1 inhibitors.If approved, Pfizer claims that sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong EFS in the BCG-nave high-risk NMIBC patien","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-meets-goal-non-muscle-151300396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BSNM7G36.USD","LU1116320901.HKD","CSTL","LU0122379950.USD","SG9999015341.SGD","LU2112291526.USD","IE00BLSP4452.SGD","LU1983299246.USD","BK4534","LU0306807586.USD","IE00BFTCPJ56.SGD","IE00B19Z3581.USD","LU1061106388.HKD","LU1571399168.USD","LU0265550946.USD","LU1066051225.USD","LU0266013472.USD","LU0070302665.USD","LU0456855351.SGD","LU0985320562.USD","LU1989772840.SGD","LU0321505439.SGD","SG9999002224.SGD","IE00B19Z3B42.SGD","LU0211331839.USD","LU1989771016.USD","IE00BBT3K403.USD","LU0106261372.USD","LU0238689110.USD","LU1934455863.HKD","LU1093756168.USD","LU2023250504.SGD","LU0965508806.USD","BK4139","BK4585","LU1894683348.USD","LU1162221912.USD","ERAS","PFE","LU0058720904.USD","LU1974910355.USD","LU1037948541.HKD","BK4539","LU2106854487.HKD","MRK","IE00BJJMRZ35.SGD","LU0289739699.SGD","SG9999001440.SGD","LU1430594728.SGD","LU1941712348.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":8,"pageCount":5,"totalSize":143,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSTL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-05","symbol":"CSTL","fiscalQuarterEnding":"2025/03","expectedEps":-0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746417600000,"reportTimeType":"post","actualEps":-0.2},{"market":"US","date":"2025-02-27","symbol":"CSTL","fiscalQuarterEnding":"2024/12","expectedEps":0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":0.32},{"market":"US","date":"2025-01-12","symbol":"CSTL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736658000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-04","symbol":"CSTL","fiscalQuarterEnding":"2024/09","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730696400000,"reportTimeType":"post","actualEps":0.08},{"market":"US","date":"2024-08-05","symbol":"CSTL","fiscalQuarterEnding":"2024/06","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":0.31}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSTL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSTL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5556,"buy":0.4444,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5556,"analysts":9,"updateTime":1702526400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSTL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSTL","date":"2025-06-17","current":-109.759225,"percent":0.183442,"low":-703.916349,"twenty":-97.732254,"median":-12.899374,"eighty":-4.847918,"high":155.734424,"avg":-50.599424,"sd":147.336455,"marketCap":556369510},"quantilePoints":[{"date":"2020-06-19","current":101.300632,"twenty":-137.181173,"median":72.096597,"eighty":89.912228,"marketCap":729871056},{"date":"2020-06-26","current":93.605957,"twenty":-130.766504,"median":72.216999,"eighty":90.734693,"marketCap":674430922},{"date":"2020-07-02","current":102.622433,"twenty":-129.220801,"median":72.241079,"eighty":91.444186,"marketCap":739394631},{"date":"2020-07-10","current":111.372149,"twenty":-123.084358,"median":72.843088,"eighty":91.857697,"marketCap":802436336},{"date":"2020-07-17","current":117.305694,"twenty":-115.1504,"median":73.469177,"eighty":92.281742,"marketCap":845187527},{"date":"2020-07-24","current":106.527432,"twenty":-106.40243,"median":74.167508,"eighty":92.916333,"marketCap":767530147},{"date":"2020-07-31","current":105.654256,"twenty":-102.767312,"median":74.396271,"eighty":93.757226,"marketCap":761238917},{"date":"2020-08-07","current":114.058572,"twenty":-101.783309,"median":74.456472,"eighty":94.202941,"marketCap":821792012},{"date":"2020-08-14","current":114.576879,"twenty":-98.400291,"median":74.981827,"eighty":94.738911,"marketCap":813266685},{"date":"2020-08-21","current":126.944083,"twenty":-97.554536,"median":75.780892,"eighty":96.467657,"marketCap":901049101},{"date":"2020-08-28","current":126.334042,"twenty":-95.952482,"median":76.635745,"eighty":97.420065,"marketCap":896719027},{"date":"2020-09-04","current":133.238602,"twenty":-93.309499,"median":76.98491,"eighty":99.303027,"marketCap":945727595},{"date":"2020-09-11","current":134.763705,"twenty":-92.601993,"median":77.514678,"eighty":100.272889,"marketCap":956552781},{"date":"2020-09-18","current":141.52962,"twenty":-91.068613,"median":78.020365,"eighty":102.449512,"marketCap":1004577242},{"date":"2020-09-25","current":137.592079,"twenty":-89.595469,"median":78.419535,"eighty":103.419182,"marketCap":976628580},{"date":"2020-10-02","current":142.611057,"twenty":-88.909949,"median":79.699487,"eighty":106.169125,"marketCap":1012253283},{"date":"2020-10-09","current":152.122158,"twenty":-87.950343,"median":80.235758,"eighty":108.912247,"marketCap":1079763078},{"date":"2020-10-16","current":138.5626,"twenty":-87.36482,"median":81.186932,"eighty":110.294181,"marketCap":983517335},{"date":"2020-10-23","current":143.747953,"twenty":-87.250969,"median":82.192491,"eighty":112.350606,"marketCap":1020322967},{"date":"2020-10-30","current":128.746478,"twenty":-87.169646,"median":82.764196,"eighty":114.265895,"marketCap":913842503},{"date":"2020-11-06","current":143.359744,"twenty":-86.063659,"median":84.023258,"eighty":116.079799,"marketCap":1017567465},{"date":"2020-11-13","current":-300.218351,"twenty":-87.950343,"median":82.764196,"eighty":115.530762,"marketCap":1002729291},{"date":"2020-11-20","current":-286.626257,"twenty":-92.601993,"median":82.192491,"eighty":115.132049,"marketCap":957331698},{"date":"2020-11-27","current":-265.105442,"twenty":-97.570801,"median":81.439776,"eighty":114.888032,"marketCap":885452175},{"date":"2020-12-04","current":-309.99512,"twenty":-109.964358,"median":80.259839,"eighty":114.369556,"marketCap":1035383700},{"date":"2020-12-11","current":-356.136701,"twenty":-134.615305,"median":79.885626,"eighty":113.96642,"marketCap":1189496581},{"date":"2020-12-18","current":-450.787075,"twenty":-141.029974,"median":78.954401,"eighty":113.756623,"marketCap":1505628832},{"date":"2020-12-24","current":-515.732815,"twenty":-143.704042,"median":78.164847,"eighty":113.491008,"marketCap":1722547602},{"date":"2020-12-31","current":-485.646593,"twenty":-146.146252,"median":77.835827,"eighty":112.857956,"marketCap":1622059619},{"date":"2021-01-08","current":-575.760614,"twenty":-151.556214,"median":77.346115,"eighty":112.012372,"marketCap":1923040451},{"date":"2021-01-15","current":-536.200125,"twenty":-153.642914,"median":76.720026,"eighty":111.384472,"marketCap":1790908417},{"date":"2021-01-22","current":-572.578418,"twenty":-155.265902,"median":76.491263,"eighty":111.374614,"marketCap":1912411915},{"date":"2021-01-29","current":-483.332268,"twenty":-167.600615,"median":75.585094,"eighty":110.83863,"marketCap":1614329774},{"date":"2021-02-05","current":-671.081866,"twenty":-169.640943,"median":74.685236,"eighty":110.157158,"marketCap":2241413434},{"date":"2021-02-12","current":-690.970595,"twenty":-171.341217,"median":74.456472,"eighty":109.561717,"marketCap":2307841788},{"date":"2021-02-19","current":-656.255723,"twenty":-173.845257,"median":74.33607,"eighty":109.348881,"marketCap":2191894116},{"date":"2021-02-26","current":-550.230719,"twenty":-178.868792,"median":74.167508,"eighty":109.144161,"marketCap":1837770601},{"date":"2021-03-05","current":-498.881637,"twenty":-200.184042,"median":73.01165,"eighty":108.912247,"marketCap":1666264669},{"date":"2021-03-12","current":-155.908697,"twenty":-197.741831,"median":72.590244,"eighty":108.442961,"marketCap":1603365036},{"date":"2021-03-19","current":-161.592235,"twenty":-187.710216,"median":72.241079,"eighty":107.618901,"marketCap":1661814548},{"date":"2021-03-26","current":-145.658896,"twenty":-181.094605,"median":72.144757,"eighty":106.811214,"marketCap":1497956087},{"date":"2021-04-01","current":-172.643561,"twenty":-179.425246,"median":72.072517,"eighty":106.28856,"marketCap":1775466377},{"date":"2021-04-09","current":-168.830246,"twenty":-179.507526,"median":71.807633,"eighty":105.852599,"marketCap":1736250252},{"date":"2021-04-16","current":-159.114795,"twenty":-178.054894,"median":70.96482,"eighty":105.703373,"marketCap":1636336556},{"date":"2021-04-23","current":-164.142541,"twenty":-177.570402,"median":70.844418,"eighty":105.135102,"marketCap":1688041893},{"date":"2021-04-30","current":-168.180083,"twenty":-176.766636,"median":70.627694,"eighty":103.731578,"marketCap":1729563976},{"date":"2021-05-07","current":-146.959621,"twenty":-175.143647,"median":69.495918,"eighty":102.75377,"marketCap":1511332740},{"date":"2021-05-14","current":-91.341496,"twenty":-173.860714,"median":69.134713,"eighty":102.6761,"marketCap":1382362194},{"date":"2021-05-21","current":-95.480588,"twenty":-173.49996,"median":68.484543,"eighty":102.639567,"marketCap":1445003222},{"date":"2021-05-28","current":-99.222328,"twenty":-172.874456,"median":67.172163,"eighty":102.507152,"marketCap":1501630711},{"date":"2021-06-04","current":-104.801825,"twenty":-172.506749,"median":65.944065,"eighty":102.127511,"marketCap":1586070816},{"date":"2021-06-11","current":-119.023747,"twenty":-171.940864,"median":65.462458,"eighty":101.207424,"marketCap":1801305386},{"date":"2021-06-18","current":-121.623097,"twenty":-171.761303,"median":65.089212,"eighty":100.776014,"marketCap":1840643952},{"date":"2021-06-25","current":-121.490646,"twenty":-171.341217,"median":64.848409,"eighty":100.452102,"marketCap":1838639439},{"date":"2021-07-02","current":-117.450892,"twenty":-171.339369,"median":64.547404,"eighty":99.99422,"marketCap":1777501796},{"date":"2021-07-09","current":-121.507203,"twenty":-171.331975,"median":62.921979,"eighty":99.596394,"marketCap":1838890003},{"date":"2021-07-16","current":-107.599851,"twenty":-170.645651,"median":-30.05226,"eighty":99.432751,"marketCap":1628416150},{"date":"2021-07-23","current":-113.907828,"twenty":-170.627605,"median":-66.775802,"eighty":99.270596,"marketCap":1723881076},{"date":"2021-07-30","current":-115.646247,"twenty":-170.259225,"median":-79.533458,"eighty":98.781094,"marketCap":1750190308},{"date":"2021-08-06","current":-118.907852,"twenty":-170.259225,"median":-80.976934,"eighty":98.358362,"marketCap":1799551438},{"date":"2021-08-13","current":-71.922702,"twenty":-169.486373,"median":-79.89941,"eighty":97.576447,"marketCap":1621785000},{"date":"2021-08-20","current":-73.898232,"twenty":-168.830246,"median":-78.110313,"eighty":97.380969,"marketCap":1666331236},{"date":"2021-08-27","current":-82.916473,"twenty":-168.790806,"median":-79.533458,"eighty":97.12033,"marketCap":1869683545},{"date":"2021-09-03","current":-85.70677,"twenty":-168.558951,"median":-80.554542,"eighty":96.729373,"marketCap":1932601958},{"date":"2021-09-10","current":-83.128535,"twenty":-168.255857,"median":-81.000595,"eighty":96.620807,"marketCap":1874465345},{"date":"2021-09-17","current":-86.298313,"twenty":-167.864896,"median":-81.677581,"eighty":96.467657,"marketCap":1945940661},{"date":"2021-09-24","current":-80.851653,"twenty":-167.600615,"median":-81.817096,"eighty":96.094956,"marketCap":1823123920},{"date":"2021-10-01","current":-72.927209,"twenty":-167.548158,"median":-81.052554,"eighty":95.725323,"marketCap":1644435629},{"date":"2021-10-08","current":-68.418088,"twenty":-166.747019,"median":-80.939604,"eighty":95.341474,"marketCap":1542759474},{"date":"2021-10-15","current":-70.962839,"twenty":-166.488822,"median":-80.193143,"eighty":94.738911,"marketCap":1600141066},{"date":"2021-10-22","current":-70.014138,"twenty":-166.318802,"median":-79.455917,"eighty":94.477414,"marketCap":1578748806},{"date":"2021-10-29","current":-69.590013,"twenty":-165.92895,"median":-79.054701,"eighty":94.395866,"marketCap":1569185207},{"date":"2021-11-05","current":-66.46488,"twenty":-165.628697,"median":-75.845859,"eighty":94.279373,"marketCap":1498716585},{"date":"2021-11-12","current":-43.948833,"twenty":-165.400692,"median":-74.221907,"eighty":94.202941,"marketCap":1307521726},{"date":"2021-11-19","current":-40.394148,"twenty":-165.136289,"median":-73.228561,"eighty":94.032207,"marketCap":1201766292},{"date":"2021-11-26","current":-36.669382,"twenty":-164.802892,"median":-72.66492,"eighty":93.911867,"marketCap":1090950790},{"date":"2021-12-03","current":-35.232201,"twenty":-164.332488,"median":-72.525406,"eighty":93.857997,"marketCap":1048193210},{"date":"2021-12-10","current":-35.043363,"twenty":-164.069675,"median":-71.699478,"eighty":93.782419,"marketCap":1042575102},{"date":"2021-12-17","current":-36.565484,"twenty":-163.125113,"median":-70.962839,"eighty":93.656387,"marketCap":1087859706},{"date":"2021-12-23","current":-36.824936,"twenty":-162.260438,"median":-70.538714,"eighty":93.390391,"marketCap":1095578673},{"date":"2021-12-31","current":-37.07574,"twenty":-161.75254,"median":-70.326651,"eighty":93.033305,"marketCap":1103040341},{"date":"2022-01-07","current":-33.80664,"twenty":-160.853861,"median":-70.081106,"eighty":92.949516,"marketCap":1005781361},{"date":"2022-01-14","current":-31.297701,"twenty":-159.513129,"median":-69.768592,"eighty":92.804142,"marketCap":931137898},{"date":"2022-01-21","current":-28.661836,"twenty":-159.163373,"median":-69.221694,"eighty":92.613304,"marketCap":852718272},{"date":"2022-01-28","current":-32.764914,"twenty":-159.153657,"median":-68.462733,"eighty":92.417037,"marketCap":974788953},{"date":"2022-02-04","current":-36.620613,"twenty":-159.037071,"median":-68.077672,"eighty":92.363653,"marketCap":1089499863},{"date":"2022-02-11","current":-37.07272,"twenty":-158.52701,"median":-67.458226,"eighty":92.230539,"marketCap":1102950479},{"date":"2022-02-18","current":-33.933566,"twenty":-157.725045,"median":-66.676942,"eighty":92.12856,"marketCap":1009557525},{"date":"2022-02-25","current":-38.121947,"twenty":-157.70385,"median":-56.620469,"eighty":92.103044,"marketCap":1134166058},{"date":"2022-03-04","current":-34.317143,"twenty":-156.502465,"median":-46.976268,"eighty":91.895938,"marketCap":1073852040},{"date":"2022-03-11","current":-32.441312,"twenty":-155.908697,"median":-44.969316,"eighty":91.848137,"marketCap":1015153549},{"date":"2022-03-18","current":-36.6396,"twenty":-155.213239,"median":-44.561123,"eighty":91.680837,"marketCap":1146526362},{"date":"2022-03-25","current":-34.406468,"twenty":-154.956761,"median":-41.163763,"eighty":91.549188,"marketCap":1076647206},{"date":"2022-04-01","current":-37.337961,"twenty":-153.952054,"median":-39.575131,"eighty":91.549188,"marketCap":1168379479},{"date":"2022-04-08","current":-26.594568,"twenty":-153.917029,"median":-38.48489,"eighty":91.417935,"marketCap":832197215},{"date":"2022-04-14","current":-21.064522,"twenty":-153.883221,"median":-38.135515,"eighty":91.392618,"marketCap":659151015},{"date":"2022-04-22","current":-18.65924,"twenty":-153.705343,"median":-38.019584,"eighty":91.277765,"marketCap":583884947},{"date":"2022-04-29","current":-18.194999,"twenty":-153.646928,"median":-37.870138,"eighty":90.837881,"marketCap":569357910},{"date":"2022-05-06","current":-17.742098,"twenty":-153.581085,"median":-37.62719,"eighty":90.669444,"marketCap":555185744},{"date":"2022-05-13","current":-10.02426,"twenty":-153.127806,"median":-37.342022,"eighty":90.431678,"marketCap":517602654},{"date":"2022-05-20","current":-11.01092,"twenty":-152.745149,"median":-37.268917,"eighty":90.138886,"marketCap":568548831},{"date":"2022-05-27","current":-11.534765,"twenty":-152.15131,"median":-37.07423,"eighty":89.945688,"marketCap":595597574},{"date":"2022-06-03","current":-9.714021,"twenty":-151.992333,"median":-36.988631,"eighty":89.740147,"marketCap":501583495},{"date":"2022-06-10","current":-9.890877,"twenty":-151.80124,"median":-36.824936,"eighty":89.553726,"marketCap":510715451},{"date":"2022-06-17","current":-8.14483,"twenty":-151.608171,"median":-36.696416,"eighty":89.491586,"marketCap":420558272},{"date":"2022-06-24","current":-12.130705,"twenty":-151.344402,"median":-36.658551,"eighty":89.461816,"marketCap":626368976},{"date":"2022-07-01","current":-11.458757,"twenty":-150.793512,"median":-36.620613,"eighty":89.366342,"marketCap":591672918},{"date":"2022-07-08","current":-13.133538,"twenty":-150.278593,"median":-36.428467,"eighty":89.249147,"marketCap":678150213},{"date":"2022-07-15","current":-12.588852,"twenty":-149.603714,"median":-36.089951,"eighty":89.1582,"marketCap":650025379},{"date":"2022-07-22","current":-12.950279,"twenty":-149.104402,"median":-35.730106,"eighty":89.071615,"marketCap":668687652},{"date":"2022-07-29","current":-14.23309,"twenty":-147.282584,"median":-35.640177,"eighty":88.843853,"marketCap":734925580},{"date":"2022-08-05","current":-15.556624,"twenty":-147.050863,"median":-35.579565,"eighty":88.468661,"marketCap":803266299},{"date":"2022-08-12","current":-20.060215,"twenty":-146.936061,"median":-35.460837,"eighty":88.420861,"marketCap":892519093},{"date":"2022-08-19","current":-18.842653,"twenty":-146.702706,"median":-35.366658,"eighty":88.334821,"marketCap":838347339},{"date":"2022-08-26","current":-18.287067,"twenty":-146.099345,"median":-35.166981,"eighty":87.890279,"marketCap":813628189},{"date":"2022-09-02","current":-16.543472,"twenty":-145.861154,"median":-35.147161,"eighty":86.833894,"marketCap":736052134},{"date":"2022-09-09","current":-17.335478,"twenty":-145.658896,"median":-35.015504,"eighty":86.661813,"marketCap":771290071},{"date":"2022-09-16","current":-16.04699,"twenty":-144.832405,"median":-34.913637,"eighty":86.238683,"marketCap":713962681},{"date":"2022-09-23","current":-14.569367,"twenty":-144.059553,"median":-34.541755,"eighty":85.557518,"marketCap":648220261},{"date":"2022-09-30","current":-15.414567,"twenty":-143.904983,"median":-34.361806,"eighty":85.203906,"marketCap":685824925},{"date":"2022-10-07","current":-15.733734,"twenty":-143.10859,"median":-34.256358,"eighty":84.606403,"marketCap":700025288},{"date":"2022-10-14","current":-13.014907,"twenty":-142.900276,"median":-33.942644,"eighty":84.37758,"marketCap":579059235},{"date":"2022-10-21","current":-12.701651,"twenty":-142.591135,"median":-33.780695,"eighty":84.023258,"marketCap":565121842},{"date":"2022-10-28","current":-13.848286,"twenty":-141.740998,"median":-33.572754,"eighty":83.567141,"marketCap":616137960},{"date":"2022-11-04","current":-10.918859,"twenty":-139.963439,"median":-33.417462,"eighty":82.764196,"marketCap":578153577},{"date":"2022-11-11","current":-11.152763,"twenty":-139.808869,"median":-32.603113,"eighty":82.764196,"marketCap":590538818},{"date":"2022-11-18","current":-10.45105,"twenty":-139.422443,"median":-31.297701,"eighty":82.306669,"marketCap":553383096},{"date":"2022-11-25","current":-10.585421,"twenty":-137.629427,"median":-30.939428,"eighty":82.215327,"marketCap":560498021},{"date":"2022-12-02","current":-12.795071,"twenty":-137.051739,"median":-30.146712,"eighty":81.917812,"marketCap":677499018},{"date":"2022-12-09","current":-11.107973,"twenty":-132.017079,"median":-29.830488,"eighty":81.521649,"marketCap":588167176},{"date":"2022-12-16","current":-11.978894,"twenty":-129.220801,"median":-29.148408,"eighty":81.035226,"marketCap":634282434},{"date":"2022-12-23","current":-11.560852,"twenty":-127.462725,"median":-28.661836,"eighty":80.413953,"marketCap":612147110},{"date":"2022-12-30","current":-11.715129,"twenty":-126.444312,"median":-28.295032,"eighty":80.255022,"marketCap":620316099},{"date":"2023-01-06","current":-11.346854,"twenty":-125.431062,"median":-25.10852,"eighty":80.129804,"marketCap":600815932},{"date":"2023-01-13","current":-13.541575,"twenty":-124.480726,"median":-21.758823,"eighty":79.936775,"marketCap":717026382},{"date":"2023-01-20","current":-13.257903,"twenty":-124.252248,"median":-20.468425,"eighty":79.81117,"marketCap":702005984},{"date":"2023-01-27","current":-12.939395,"twenty":-123.914499,"median":-20.219799,"eighty":79.508532,"marketCap":685140976},{"date":"2023-02-03","current":-14.084034,"twenty":-123.669464,"median":-19.981754,"eighty":79.275321,"marketCap":745749600},{"date":"2023-02-10","current":-13.1733,"twenty":-123.391317,"median":-19.773366,"eighty":78.392678,"marketCap":697526216},{"date":"2023-02-17","current":-12.939395,"twenty":-122.237123,"median":-19.352035,"eighty":78.237088,"marketCap":685140976},{"date":"2023-02-24","current":-12.123218,"twenty":-121.646854,"median":-19.194328,"eighty":78.044446,"marketCap":641924391},{"date":"2023-03-03","current":-9.769225,"twenty":-121.623097,"median":-18.990416,"eighty":77.996285,"marketCap":655886202},{"date":"2023-03-10","current":-7.706921,"twenty":-121.507203,"median":-18.763163,"eighty":77.67537,"marketCap":517427243},{"date":"2023-03-17","current":-8.470884,"twenty":-121.490646,"median":-18.651096,"eighty":77.514678,"marketCap":568718182},{"date":"2023-03-24","current":-8.910261,"twenty":-121.407864,"median":-18.327158,"eighty":77.346115,"marketCap":598217116},{"date":"2023-03-31","current":-8.993387,"twenty":-120.530377,"median":-18.243867,"eighty":76.98491,"marketCap":603797995},{"date":"2023-04-06","current":-8.827136,"twenty":-120.25223,"median":-18.109752,"eighty":76.792267,"marketCap":592636236},{"date":"2023-04-14","current":-9.233586,"twenty":-119.573419,"median":-17.654644,"eighty":76.705578,"marketCap":619924514},{"date":"2023-04-21","current":-9.5476,"twenty":-119.262158,"median":-17.35912,"eighty":76.599624,"marketCap":641006751},{"date":"2023-04-28","current":-8.804302,"twenty":-119.063482,"median":-17.187715,"eighty":76.440694,"marketCap":591103228},{"date":"2023-05-05","current":-8.18984,"twenty":-118.984012,"median":-16.797623,"eighty":75.90611,"marketCap":587367135},{"date":"2023-05-12","current":-8.442866,"twenty":-118.921097,"median":-16.759205,"eighty":75.624254,"marketCap":605513871},{"date":"2023-05-19","current":-8.747984,"twenty":-118.854872,"median":-16.543472,"eighty":75.272328,"marketCap":627396699},{"date":"2023-05-26","current":-9.369385,"twenty":-118.099901,"median":-16.162244,"eighty":74.854441,"marketCap":671962947},{"date":"2023-06-02","current":-7.832628,"twenty":-117.894602,"median":-15.796084,"eighty":74.668379,"marketCap":561748214},{"date":"2023-06-09","current":-5.33214,"twenty":-117.642945,"median":-15.68645,"eighty":74.514265,"marketCap":382415768},{"date":"2023-06-16","current":-4.986091,"twenty":-117.464137,"median":-15.580163,"eighty":74.456472,"marketCap":357597438},{"date":"2023-06-23","current":-4.930276,"twenty":-117.424402,"median":-15.417523,"eighty":74.456472,"marketCap":353594482},{"date":"2023-06-30","current":-4.933997,"twenty":-117.219102,"median":-15.257939,"eighty":74.432392,"marketCap":353861345},{"date":"2023-07-07","current":-4.941439,"twenty":-116.556848,"median":-15.108846,"eighty":74.33607,"marketCap":354395073},{"date":"2023-07-14","current":-6.02796,"twenty":-116.507179,"median":-14.859223,"eighty":74.263829,"marketCap":432319291},{"date":"2023-07-21","current":-6.214009,"twenty":-115.646247,"median":-14.557546,"eighty":74.167508,"marketCap":445662479},{"date":"2023-07-28","current":-5.894006,"twenty":-115.613135,"median":-14.258542,"eighty":74.167508,"marketCap":422712195},{"date":"2023-08-04","current":-5.663815,"twenty":-115.513796,"median":-14.240825,"eighty":73.926704,"marketCap":503218594},{"date":"2023-08-11","current":-5.280594,"twenty":-114.553527,"median":-14.178591,"eighty":73.01165,"marketCap":469170240},{"date":"2023-08-18","current":-5.208175,"twenty":-113.907828,"median":-14.052198,"eighty":72.867168,"marketCap":462735905},{"date":"2023-08-25","current":-5.64571,"twenty":-113.791934,"median":-13.89557,"eighty":72.843088,"marketCap":501610010},{"date":"2023-09-01","current":-6.013843,"twenty":-113.659483,"median":-13.834522,"eighty":72.3374,"marketCap":534317879},{"date":"2023-09-08","current":-5.66985,"twenty":-113.552925,"median":-13.793063,"eighty":72.260343,"marketCap":503754789},{"date":"2023-09-15","current":-5.310769,"twenty":-113.447412,"median":-13.581503,"eighty":72.241079,"marketCap":471851212},{"date":"2023-09-22","current":-5.027126,"twenty":-113.123056,"median":-13.47439,"eighty":72.241079,"marketCap":446650068},{"date":"2023-09-29","current":-5.247402,"twenty":-111.576691,"median":-13.437064,"eighty":72.20255,"marketCap":466221169},{"date":"2023-10-06","current":-4.483979,"twenty":-111.103179,"median":-13.330065,"eighty":72.115861,"marketCap":398392558},{"date":"2023-10-13","current":-3.678311,"twenty":-110.692581,"median":-13.257903,"eighty":72.096597,"marketCap":326810584},{"date":"2023-10-20","current":-3.862378,"twenty":-109.828339,"median":-13.190718,"eighty":72.058068,"marketCap":343164518},{"date":"2023-10-27","current":-3.946867,"twenty":-109.228998,"median":-13.161054,"eighty":72.033988,"marketCap":350671242},{"date":"2023-11-03","current":-5.912031,"twenty":-107.583295,"median":-13.139027,"eighty":71.942483,"marketCap":446381971},{"date":"2023-11-10","current":-6.105341,"twenty":-107.470712,"median":-13.073766,"eighty":71.720944,"marketCap":460977687},{"date":"2023-11-17","current":-6.860935,"twenty":-106.821702,"median":-13.014907,"eighty":71.306761,"marketCap":518028049},{"date":"2023-11-24","current":-7.085475,"twenty":-104.967388,"median":-12.997175,"eighty":71.037061,"marketCap":534981694},{"date":"2023-12-01","current":-7.12468,"twenty":-104.801825,"median":-12.950279,"eighty":70.892579,"marketCap":537941854},{"date":"2023-12-08","current":-6.878756,"twenty":-104.621466,"median":-12.939395,"eighty":70.868499,"marketCap":519373576},{"date":"2023-12-15","current":-7.345656,"twenty":-102.303773,"median":-12.93329,"eighty":70.844418,"marketCap":554626394},{"date":"2023-12-22","current":-7.766222,"twenty":-101.653193,"median":-12.899374,"eighty":70.675856,"marketCap":586380840},{"date":"2023-12-29","current":-7.994326,"twenty":-101.138387,"median":-12.831107,"eighty":70.661407,"marketCap":603603591},{"date":"2024-01-05","current":-7.242296,"twenty":-100.480612,"median":-12.765211,"eighty":70.642143,"marketCap":546822335},{"date":"2024-01-12","current":-7.345656,"twenty":-99.17597,"median":-12.686153,"eighty":70.492844,"marketCap":554626394},{"date":"2024-01-19","current":-6.957166,"twenty":-98.990539,"median":-12.535401,"eighty":70.049766,"marketCap":525293896},{"date":"2024-01-26","current":-7.356348,"twenty":-98.377953,"median":-12.367076,"eighty":69.495918,"marketCap":555433710},{"date":"2024-02-02","current":-8.439841,"twenty":-98.245502,"median":-12.314821,"eighty":69.375516,"marketCap":637241776},{"date":"2024-02-09","current":-8.500431,"twenty":-97.897818,"median":-12.148101,"eighty":69.255114,"marketCap":641816569},{"date":"2024-02-16","current":-8.867536,"twenty":-97.587065,"median":-12.126962,"eighty":69.014311,"marketCap":669534434},{"date":"2024-02-23","current":-8.682202,"twenty":-97.554536,"median":-12.050186,"eighty":68.879461,"marketCap":655540949},{"date":"2024-03-01","current":-8.626783,"twenty":-97.496408,"median":-11.968941,"eighty":68.556784,"marketCap":495746692},{"date":"2024-03-08","current":-9.911724,"twenty":-97.444174,"median":-11.921994,"eighty":68.446014,"marketCap":569587147},{"date":"2024-03-15","current":-9.219098,"twenty":-97.381259,"median":-11.8495,"eighty":67.954775,"marketCap":529784671},{"date":"2024-03-22","current":-10.07891,"twenty":-97.328279,"median":-11.779827,"eighty":66.774837,"marketCap":579194641},{"date":"2024-03-28","current":-10.164891,"twenty":-96.980595,"median":-11.747478,"eighty":66.394368,"marketCap":584135638},{"date":"2024-04-05","current":-10.145784,"twenty":-96.034573,"median":-11.715129,"eighty":65.869416,"marketCap":583037638},{"date":"2024-04-12","current":-9.975623,"twenty":-95.509954,"median":-11.674233,"eighty":65.541923,"marketCap":573259148},{"date":"2024-04-19","current":-9.21713,"twenty":-93.841259,"median":-11.590712,"eighty":65.486538,"marketCap":529671590},{"date":"2024-04-26","current":-9.365948,"twenty":-92.601993,"median":-11.540343,"eighty":65.296304,"marketCap":538223579},{"date":"2024-05-03","current":-20.460076,"twenty":-92.472226,"median":-11.516062,"eighty":65.156637,"marketCap":630088496},{"date":"2024-05-10","current":-21.891395,"twenty":-91.785206,"median":-11.553387,"eighty":65.07958,"marketCap":674167408},{"date":"2024-05-17","current":-21.712105,"twenty":-90.954077,"median":-11.630526,"eighty":64.939914,"marketCap":668645972},{"date":"2024-05-24","current":-21.281807,"twenty":-90.477253,"median":-11.705647,"eighty":64.858041,"marketCap":655394524},{"date":"2024-05-31","current":-21.70314,"twenty":-90.243501,"median":-11.725082,"eighty":64.752087,"marketCap":668369900},{"date":"2024-06-07","current":-20.645325,"twenty":-89.767451,"median":-11.754943,"eighty":64.597973,"marketCap":635793424},{"date":"2024-06-14","current":-20.331566,"twenty":-89.137652,"median":-11.784803,"eighty":64.569077,"marketCap":626130910},{"date":"2024-06-21","current":-18.888276,"twenty":-88.682246,"median":-11.8495,"eighty":64.511283,"marketCap":581683345},{"date":"2024-06-28","current":-18.968957,"twenty":-88.19431,"median":-11.87936,"eighty":63.91409,"marketCap":584167992},{"date":"2024-07-05","current":-19.049638,"twenty":-87.429878,"median":-11.962718,"eighty":62.979772,"marketCap":586652638},{"date":"2024-07-12","current":-16.575426,"twenty":-87.283498,"median":-11.973917,"eighty":62.661912,"marketCap":510456813},{"date":"2024-07-15","current":-16.629213,"twenty":-87.267233,"median":-11.978894,"eighty":62.498165,"marketCap":512113244},{"date":"2024-08-02","current":-20.654289,"twenty":-86.610826,"median":-11.921994,"eighty":63.018301,"marketCap":636069496},{"date":"2024-08-09","current":-249.174378,"twenty":-87.299762,"median":-11.921994,"eighty":63.018301,"marketCap":772191398},{"date":"2024-08-16","current":-242.909218,"twenty":-92.450772,"median":-11.921994,"eighty":63.018301,"marketCap":752775666},{"date":"2024-08-23","current":-246.399807,"twenty":-97.318345,"median":-11.921994,"eighty":63.018301,"marketCap":763593002},{"date":"2024-08-30","current":-266.627325,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":826278080},{"date":"2024-09-06","current":-263.852754,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":817679684},{"date":"2024-09-13","current":-274.593029,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":850963796},{"date":"2024-09-20","current":-273.250494,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":846803282},{"date":"2024-09-27","current":-250.606415,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":776629280},{"date":"2024-10-04","current":-254.365511,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":788278719},{"date":"2024-10-11","current":-253.291484,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":784950308},{"date":"2024-10-18","current":-295.894574,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":916977285},{"date":"2024-10-25","current":-284.617286,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":882028968},{"date":"2024-10-31","current":-309.140913,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":958027690},{"date":"2024-11-08","current":153.567604,"twenty":-91.563351,"median":-11.784803,"eighty":64.853225,"marketCap":932923196},{"date":"2024-11-15","current":142.134171,"twenty":-90.404405,"median":-11.754943,"eighty":65.240919,"marketCap":863465089},{"date":"2024-11-22","current":133.144173,"twenty":-90.404405,"median":-11.754943,"eighty":65.474498,"marketCap":808850852},{"date":"2024-11-29","current":139.598531,"twenty":-90.404405,"median":-11.754943,"eighty":66.977112,"marketCap":848061074},{"date":"2024-12-06","current":148.265811,"twenty":-90.404405,"median":-11.754943,"eighty":69.332172,"marketCap":900714800},{"date":"2024-12-13","current":134.250635,"twenty":-90.404405,"median":-11.754943,"eighty":70.85405,"marketCap":815572605},{"date":"2024-12-20","current":124.891816,"twenty":-90.404405,"median":-11.754943,"eighty":71.990643,"marketCap":758717784},{"date":"2024-12-27","current":124.937919,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":758997857},{"date":"2025-01-03","current":129.271559,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":785324720},{"date":"2025-01-10","current":150.847554,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":916398888},{"date":"2025-01-17","current":115.671306,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":702703182},{"date":"2025-01-24","current":122.171766,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":742193476},{"date":"2025-01-31","current":130.101405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":790366034},{"date":"2025-02-07","current":128.303405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":779443186},{"date":"2025-02-14","current":127.289149,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":773281580},{"date":"2025-02-21","current":120.558176,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":732390921},{"date":"2025-02-28","current":38.806499,"twenty":-90.477253,"median":-11.764897,"eighty":76.356928,"marketCap":708024569},{"date":"2025-03-07","current":32.178981,"twenty":-90.550101,"median":-11.77485,"eighty":73.454249,"marketCap":587105504},{"date":"2025-03-14","current":29.318974,"twenty":-90.550101,"median":-11.77485,"eighty":33.288601,"marketCap":534924684},{"date":"2025-03-21","current":31.366301,"twenty":-90.550101,"median":-11.77485,"eighty":31.49758,"marketCap":572278167},{"date":"2025-03-28","current":31.413187,"twenty":-90.550101,"median":-11.77485,"eighty":31.375678,"marketCap":573133590},{"date":"2025-04-04","current":29.990998,"twenty":-90.550101,"median":-11.77485,"eighty":31.063109,"marketCap":547185751},{"date":"2025-04-11","current":30.162911,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":550322303},{"date":"2025-04-17","current":33.226087,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":606209957},{"date":"2025-04-25","current":33.089862,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":603724531},{"date":"2025-05-02","current":30.528678,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":556995733},{"date":"2025-05-09","current":-98.025753,"twenty":-95.154431,"median":-11.87936,"eighty":29.478384,"marketCap":496892541},{"date":"2025-05-16","current":-93.867775,"twenty":-96.90247,"median":-11.978894,"eighty":-3.786337,"marketCap":475815751},{"date":"2025-05-23","current":-90.507217,"twenty":-96.90247,"median":-12.148101,"eighty":-3.979456,"marketCap":458781085},{"date":"2025-05-30","current":-90.848969,"twenty":-96.90247,"median":-12.322286,"eighty":-4.309569,"marketCap":460513424},{"date":"2025-06-06","current":-96.943539,"twenty":-96.977714,"median":-12.588852,"eighty":-4.550363,"marketCap":491406801},{"date":"2025-06-13","current":-107.196088,"twenty":-97.40775,"median":-12.795071,"eighty":-4.74909,"marketCap":543376968},{"date":"2025-06-17","current":-109.759225,"twenty":-97.732254,"median":-12.899374,"eighty":-4.847918,"marketCap":556369510}],"updateTime":1750241018731}}}